The company reported second-quarter 2026 total revenue of $33.4 million, with its flagship product XPOVIO contributing $30.8 million. While this figure marks a modest increase from the $29.7 million earned in the same period last year, Karyopharm faces a tightening financial timeline. With $65.4 million in cash and equivalents as of June 30, management is actively exploring financing alternatives to extend its operational runway beyond September 2026, when a $15.8 million debt payment falls due.

Clinical efforts remain anchored by the Phase 3 SENTRY trial, which demonstrated that selinexor can induce rapid and sustained spleen volume reduction. Following the trial's success, the company is prioritizing its myelofibrosis and multiple myeloma programs, having recently deprioritized its endometrial cancer pipeline after the XPORT-EC-042 trial failed to meet its primary progression-free survival endpoint. Karyopharm has reaffirmed its full-year 2026 revenue guidance of $130 million to $150 million, banking on the potential regulatory success of its lead candidate to bolster its long-term market position.